GlassScriptPhysician profile
Elina Badiner
NPI 1598238149
$5,224.15
in general payments reported to CMS, 2019-2025
30 companies · $1,071 in 2025
The $1,071 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $861 · 2022: $1,016 · 2023: $1,096 · 2024: $1,180 · 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,283 · Education: $63.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,283.23 |
| Education | $63.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $909.61 | 2021-2025 | Verquvo, Capvaxive, Belsomra |
| Astrazeneca Pharmaceuticals LP | $644.21 | 2021-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.28 | 2021-2024 | Jardiance, Ofev |
| Genzyme Corporation | $353.94 | 2022-2025 | |
| Edwards Lifesciences Corporation | $320.87 | 2022-2025 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $307.87 | 2021-2022 | |
| Amgen INC. | $266.64 | 2021-2023 | Repatha |
| Verona Pharma, INC. | $208.75 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $167.76 | 2025 | |
| Amarin Pharma, INC. | $160.54 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.80 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $149.45 | 2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $145.00 | 2023 | Xarelto |
| Esperion Therapeutics, INC. | $144.47 | 2021-2025 | Nexletol |
| Boston Scientific Corporation | $143.14 | 2022-2024 | Varithena Administration Pack |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $127.01 | 2021-2023 | Evkeeza |
| Pfizer INC. | $92.17 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $77.55 | 2021-2025 | Eliquis, Camzyos |
| Heartflow, INC. | $65.11 | 2024-2025 | |
| Glaxosmithkline, LLC. | $63.28 | 2021-2025 | Nucala |
| Scpharmaceuticals INC. | $62.28 | 2023-2024 | |
| Insmed, INC. | $49.78 | 2022 | |
| Mylan Specialty L.P. | $47.62 | 2021-2024 | Yupelri |
| Cvrx, INC. | $42.60 | 2023 | Barostim Neo System |
| Medtronic, INC. | $42.25 | 2024 | Corevalve Evolut R |
| United Therapeutics Corporation | $26.69 | 2025 | Tyvaso |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.24 | 2021 | |
| Philips North America LLC | $23.86 | 2024 | (Ck7) Extended Holter |
| Kiniksa Pharmaceuticals International, Plc | $23.10 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $19.28 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elina Badiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.